Todos
← Back to Squawk list
Aviation And Travel Stocks Surge After Preliminary Results Show Pfizer Covid-19 Vaccine 90% Effective
Pfizer announces that preliminary data shows their Covid-19 vaccine to be 90% effective. Airline and aerospace stocks prices increased by at least 10% in response to the announcement. (www.gatechecked.com) Más...Sort type: [Top] [Newest]
Great News... This is what we needed.
Good news....but equity markets tend to over-react to sudden news, good or bad. Watch what happens to these stock prices over the next few few weeks.
Yes they did! Shares went up by 20% give or take. However in the following two days they have dropped by over half of what they gained. Let's see if they level off or continue their downward slide to pre Phizer announcement values.
Pfizer
Clearly this is better-than-expected good news (medium term) for the aviation industry. Unforch, the near term Covid spread in N. America and Europe, is accelerating, and will continue to cause much health suffering.
Well, its not 'Pfizer's vaccine' but rather BionTech's. Pfizer just did part of the funding and has the right to produce the vaccine in its facilities.
First,it is spelled BioNTech. Up until 2020, that tiny company had manufactured and dosed a grand total of 250 persons with vaccines. Yes that's 250 persons total.
It requires an established global producer like Pfizer to conduct regulatory testing, then scale up manufacturing to tens of millions of doses.
The fledgling, untried mRMA technoogy requires lipid nanoparticles to encapsulate the RNA and cold chain storage temperatures about -70 degC,
It is all rather delicate, therefore not suitable for billions of people in India, Brazil, Africa, Asia, etc. Luckily, there are dozens of other vaccine candidates being develpoed, most of which use more proven technology that needs less specialized handling.
One candidate, from a Chinese Biotech, withstands 7 days at room temperatures.
It requires an established global producer like Pfizer to conduct regulatory testing, then scale up manufacturing to tens of millions of doses.
The fledgling, untried mRMA technoogy requires lipid nanoparticles to encapsulate the RNA and cold chain storage temperatures about -70 degC,
It is all rather delicate, therefore not suitable for billions of people in India, Brazil, Africa, Asia, etc. Luckily, there are dozens of other vaccine candidates being develpoed, most of which use more proven technology that needs less specialized handling.
One candidate, from a Chinese Biotech, withstands 7 days at room temperatures.
My understanding is that the similar mRNA Moderna vaccine only requires storage at -4 C but as to why two similar vaccines require such widely different storage temperatures I don't know.
Well done you discovered a typo. You are right about Pfizer but still the vaccine was invented by BioNTech no mattwr how small the company was or is. Curevac also says that its vaccine can withstand a few days at room temperatures. But they still have to prove effectiness and safety. I am not eager to try a Chinese or a Russian product by the way.